A Trial to Confirm a Sustained Virological Suppression Defined as HIV-RNA <50 Copies/ml of 3 Different Doses of Fozivudine in Context to a Standard Zidovudine Based Antiretroviral Therapy Regimen

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

June 30, 2014

Study Completion Date

February 28, 2017

Conditions
HIV-1 Infection
Interventions
DRUG

FZD

DRUG

3TC

DRUG

EFV

DRUG

AZT

Trial Locations (2)

BPV3

Service des Maladies Infectieuses et Tropicales, CHU de Treichville,, Abidjan

PO Box 2410

NIMR - Mbeya Medical Research Programme,, Mbeya

All Listed Sponsors
collaborator

European and Developing Countries Clinical Trials Partnership (EDCTP)

OTHER_GOV

collaborator

German Federal Ministry of Education and Research

OTHER_GOV

collaborator

National Institute for Medical Research, Tanzania

OTHER_GOV

collaborator

Treichville Academic hospital center, Division of infectious and tropical diseases (SMIT)

UNKNOWN

collaborator

ANRS, Emerging Infectious Diseases

OTHER_GOV

collaborator

Kumasi Centre for Collaborative Research (KCCR)

OTHER

collaborator

Bernhard Nocht Institute for Tropical Medicine

OTHER_GOV

collaborator

Pharmaceutical Company (Chiracon GmbH)

UNKNOWN

collaborator

Pharmaceutical Company (STADA Vietnam Joint Venture Co. Ltd.)

UNKNOWN

lead

Michael Hoelscher

OTHER